Cargando…

Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer

BACKGROUND: CD276 (also known as B7-H3), a newly discovered immunoregulatory protein that belongs to the B7 family, is a significant and attractive target for cancer immunotherapy. Existing evidence demonstrates its pivotal role in the tumorigenesis of some cancers. However, there still lacks a syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jinye, Sun, Yaoqi, Sulaiman, Zubaidan, Li, Caixia, Cheng, Zhongping, Liu, Shupeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901449/
https://www.ncbi.nlm.nih.gov/pubmed/36756390
http://dx.doi.org/10.2147/IJGM.S395553
_version_ 1784883032972328960
author Ding, Jinye
Sun, Yaoqi
Sulaiman, Zubaidan
Li, Caixia
Cheng, Zhongping
Liu, Shupeng
author_facet Ding, Jinye
Sun, Yaoqi
Sulaiman, Zubaidan
Li, Caixia
Cheng, Zhongping
Liu, Shupeng
author_sort Ding, Jinye
collection PubMed
description BACKGROUND: CD276 (also known as B7-H3), a newly discovered immunoregulatory protein that belongs to the B7 family, is a significant and attractive target for cancer immunotherapy. Existing evidence demonstrates its pivotal role in the tumorigenesis of some cancers. However, there still lacks a systematic and comprehensive pan-cancer analysis of the role of CD276 in tumor immunology and prognosis. METHODS: We explored and validated the mRNA and protein expression levels of CD276 in multiple tumors through public databases and clinical tissues specimens. The Univariate Cox regression analysis and Kaplan–Meier analysis were applied to assess the prognostic value of CD276. The correlation between CD276 expression and clinical characteristics and immunological features in diverse tumors was also explored. GSEA was performed to illuminate the biological function and involved pathways of CD276. Moreover, the CellMiner database was used to interpret the relationship between CD276 and multiple chemotherapeutic agents. CCK-8 assay was performed to validate the biological function of CD276 in vitro. RESULTS: In general, CD276 was differentially expressed between most tumor tissues and their corresponding normal tissues. Higher expression levels of CD276 were associated with poorer survival outcomes in most tumor cohorts from TCGA. There was a close correlation between CD276 expression and clinical features, the infiltration levels of specific immune cells, immune subtypes, TMB, MSI, MMR, recognized immunoregulatory genes and drug sensitivity across diverse human cancers. The scRNA-seq data analysis further revealed that CD276 was mainly expressed on the tumor infiltrating macrophages. Additionally, in vitro experiments showed that knockdown of CD276 inhibited the proliferation of ovarian cancer (OV) and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) cell lines. CONCLUSION: CD276 is a potent biomarker for predicting the prognosis and immunological features in some tumors, and it may play a critical role in the tumor immune microenvironment (TIME) through macrophage-associated signaling.
format Online
Article
Text
id pubmed-9901449
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99014492023-02-07 Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer Ding, Jinye Sun, Yaoqi Sulaiman, Zubaidan Li, Caixia Cheng, Zhongping Liu, Shupeng Int J Gen Med Original Research BACKGROUND: CD276 (also known as B7-H3), a newly discovered immunoregulatory protein that belongs to the B7 family, is a significant and attractive target for cancer immunotherapy. Existing evidence demonstrates its pivotal role in the tumorigenesis of some cancers. However, there still lacks a systematic and comprehensive pan-cancer analysis of the role of CD276 in tumor immunology and prognosis. METHODS: We explored and validated the mRNA and protein expression levels of CD276 in multiple tumors through public databases and clinical tissues specimens. The Univariate Cox regression analysis and Kaplan–Meier analysis were applied to assess the prognostic value of CD276. The correlation between CD276 expression and clinical characteristics and immunological features in diverse tumors was also explored. GSEA was performed to illuminate the biological function and involved pathways of CD276. Moreover, the CellMiner database was used to interpret the relationship between CD276 and multiple chemotherapeutic agents. CCK-8 assay was performed to validate the biological function of CD276 in vitro. RESULTS: In general, CD276 was differentially expressed between most tumor tissues and their corresponding normal tissues. Higher expression levels of CD276 were associated with poorer survival outcomes in most tumor cohorts from TCGA. There was a close correlation between CD276 expression and clinical features, the infiltration levels of specific immune cells, immune subtypes, TMB, MSI, MMR, recognized immunoregulatory genes and drug sensitivity across diverse human cancers. The scRNA-seq data analysis further revealed that CD276 was mainly expressed on the tumor infiltrating macrophages. Additionally, in vitro experiments showed that knockdown of CD276 inhibited the proliferation of ovarian cancer (OV) and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) cell lines. CONCLUSION: CD276 is a potent biomarker for predicting the prognosis and immunological features in some tumors, and it may play a critical role in the tumor immune microenvironment (TIME) through macrophage-associated signaling. Dove 2023-02-02 /pmc/articles/PMC9901449/ /pubmed/36756390 http://dx.doi.org/10.2147/IJGM.S395553 Text en © 2023 Ding et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ding, Jinye
Sun, Yaoqi
Sulaiman, Zubaidan
Li, Caixia
Cheng, Zhongping
Liu, Shupeng
Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer
title Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer
title_full Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer
title_fullStr Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer
title_full_unstemmed Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer
title_short Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer
title_sort comprehensive analysis reveals distinct immunological and prognostic characteristics of cd276/b7-h3 in pan-cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901449/
https://www.ncbi.nlm.nih.gov/pubmed/36756390
http://dx.doi.org/10.2147/IJGM.S395553
work_keys_str_mv AT dingjinye comprehensiveanalysisrevealsdistinctimmunologicalandprognosticcharacteristicsofcd276b7h3inpancancer
AT sunyaoqi comprehensiveanalysisrevealsdistinctimmunologicalandprognosticcharacteristicsofcd276b7h3inpancancer
AT sulaimanzubaidan comprehensiveanalysisrevealsdistinctimmunologicalandprognosticcharacteristicsofcd276b7h3inpancancer
AT licaixia comprehensiveanalysisrevealsdistinctimmunologicalandprognosticcharacteristicsofcd276b7h3inpancancer
AT chengzhongping comprehensiveanalysisrevealsdistinctimmunologicalandprognosticcharacteristicsofcd276b7h3inpancancer
AT liushupeng comprehensiveanalysisrevealsdistinctimmunologicalandprognosticcharacteristicsofcd276b7h3inpancancer